GlycoMimetics, Inc. (GLYC) financial statements (2021 and earlier)

Company profile

Business Address 9708 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments137158210124404755
Cash and cash equivalents137158210124404755
Receivables0000000
Prepaid expense1423001
Deposits current assets    000
Other undisclosed current assets0000  0
Total current assets:138163212127414756
Noncurrent Assets
Operating lease, right-of-use asset23
Property, plant and equipment1111110
Prepaid expense2220111
Other undisclosed noncurrent assets00000  
Total noncurrent assets:5531211
TOTAL ASSETS:143168215129424857
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities121098687
Accounts payable2133211
Accrued liabilities9944365
Employee-related liabilities  22111
Debt 1     
Deferred rent credit  0
Deferred revenue and credits00 0
Other undisclosed current liabilities1     (0)
Total current liabilities:121198686
Noncurrent Liabilities
Long-term debt and lease obligation23     
Operating lease, liability23
Liabilities, other than long-term debt0 1110 
Deferred revenue and credits110 
Accounts payable and accrued liabilities0      
Deferred rent credit  1
Total noncurrent liabilities:231110 
Total liabilities:151499786
Stockholders' equity
Stockholders' equity attributable to parent128154205120354051
Common stock0000000
Additional paid in capital438413406272154128125
Accumulated deficit(309)(258)(201)(152)(119)(87)(74)
Total stockholders' equity:128154205120354051
TOTAL LIABILITIES AND EQUITY:143168215129424857

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:10   02015
Operating expenses(62)(61)(52)(34)(32)(33)(33)
Other undisclosed operating income      7
Operating loss:(52)(61)(52)(34)(32)(13)(11)
Nonoperating income
(Other Nonoperating income)
   1000
Loss before gain (loss) on sale of properties:(52)(61)(52)(33)(32)(13)(11)
Other undisclosed net income033    
Net loss available to common stockholders, diluted:(51)(58)(48)(33)(32)(13)(11)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(51)(58)(48)(33)(32)(13)(11)
Comprehensive loss, net of tax, attributable to parent:(51)(58)(48)(33)(32)(13)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: